Ash 2024 Doris Hansen Md On Ide And Cilta Cel In Relapsed Refractory Multiple Myeloma

Media Summary: Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by ... Improving Lives Finding the Cure Founded in 1990, the International Watch the full course and our most up-to-date content here: Create a free account to track ...

Ash 2024 Doris Hansen Md On Ide And Cilta Cel In Relapsed Refractory Multiple Myeloma - Detailed Analysis & Overview

Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by ... Improving Lives Finding the Cure Founded in 1990, the International Watch the full course and our most up-to-date content here: Create a free account to track ... 2025 American Society of Hematology Expert Insights: Early During the 67th American Society of Hematology (

Photo Gallery

$ASH 2024: Doris Hansen, MD on Ide and Cilta-cel in Relapsed/Refractory Multiple Myeloma$

ASH 2024: Doris Hansen, MD on Toxicity & Response in Idecabtagene Vicleucel Therapy

$CAR-T Cell Therapy Cilta-cel for Relapsed/Refractory Myeloma | Doris Hansen, MD | ASCO 2023$

Comparing the safety and efficacy of cilta-cel and ide-cel in R/R myeloma using real-world data

Toxicities associated with ide-cel in KarMMa

Real-world experiences with ide-cel in R/R multiple myeloma

Doris Hansen, MD: Bridging response, low burden improve cilta-cel outcomes in MM

Dr. Doris Hansen at ASCO 2023: Abstract No. 8012

Dr. Doris Hansen at ASCO 2022: Abstract No. 8042

$CARTITUDE-4 ASH 2024 – Cilta-cel vs. SoC in Lenalidomide Refractory MM After 1–3 Lines of Therapy$

Links to Early Responses in Multiple Myeloma Patients | Doris K Hansen, MD | ASH 2023 #myeloma

ASH23: Frontline Treatment DRd vs. VRd for Transplant-Ineligible Myeloma Patients | Doris Hansen, MD

View Detailed Profile

ASH 2024: Doris Hansen, MD on Ide and Cilta-cel in Relapsed/Refractory Multiple Myeloma

ASH 2024: Doris Hansen, MD on Ide and Cilta-cel in Relapsed/Refractory Multiple Myeloma

Doris Hansen

ASH 2024: Doris Hansen, MD on Toxicity & Response in Idecabtagene Vicleucel Therapy

ASH 2024: Doris Hansen, MD on Toxicity & Response in Idecabtagene Vicleucel Therapy

At

CAR-T Cell Therapy Cilta-cel for Relapsed/Refractory Myeloma | Doris Hansen, MD | ASCO 2023

CAR-T Cell Therapy Cilta-cel for Relapsed/Refractory Myeloma | Doris Hansen, MD | ASCO 2023

Interview with

Comparing the safety and efficacy of cilta-cel and ide-cel in R/R myeloma using real-world data

Comparing the safety and efficacy of cilta-cel and ide-cel in R/R myeloma using real-world data

Dr Doris Hansen

Toxicities associated with ide-cel in KarMMa

Toxicities associated with ide-cel in KarMMa

Doris

Real-world experiences with ide-cel in R/R multiple myeloma

Real-world experiences with ide-cel in R/R multiple myeloma

Doris Hansen

Doris Hansen, MD: Bridging response, low burden improve cilta-cel outcomes in MM

Doris Hansen, MD: Bridging response, low burden improve cilta-cel outcomes in MM

At #ASH25,

Dr. Doris Hansen at ASCO 2023: Abstract No. 8012

Dr. Doris Hansen at ASCO 2023: Abstract No. 8012

At ASCO 2023:

Dr. Doris Hansen at ASCO 2022: Abstract No. 8042

Dr. Doris Hansen at ASCO 2022: Abstract No. 8042

Dr

CARTITUDE-4 ASH 2024 – Cilta-cel vs. SoC in Lenalidomide Refractory MM After 1–3 Lines of Therapy

CARTITUDE-4 ASH 2024 – Cilta-cel vs. SoC in Lenalidomide Refractory MM After 1–3 Lines of Therapy

Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by ...

Links to Early Responses in Multiple Myeloma Patients | Doris K Hansen, MD | ASH 2023 #myeloma

Links to Early Responses in Multiple Myeloma Patients | Doris K Hansen, MD | ASH 2023 #myeloma

Interview with

ASH23: Frontline Treatment DRd vs. VRd for Transplant-Ineligible Myeloma Patients | Doris Hansen, MD

ASH23: Frontline Treatment DRd vs. VRd for Transplant-Ineligible Myeloma Patients | Doris Hansen, MD

Improving Lives | Finding the Cure Founded in 1990, the International

Factors to consider when choosing between cilta-cel and ide-cel for R/R multiple myeloma

Factors to consider when choosing between cilta-cel and ide-cel for R/R multiple myeloma

Yi Lin,

Valuable Predictors Identified for Ide-Cel Therapy in Multiple Myeloma

Valuable Predictors Identified for Ide-Cel Therapy in Multiple Myeloma

Doris Hansen

Charting the Path Forward in Multiple Myeloma Care | Doris Hansen, MD | Tampa RT

Charting the Path Forward in Multiple Myeloma Care | Doris Hansen, MD | Tampa RT

Watch the full course and our most up-to-date content here: https://linktr.ee/HealthTreeUniversity Create a free account to track ...

Relapsed Multiple Myeloma

Relapsed Multiple Myeloma

ASH

ASH 2025 Expert Insights: Early Cilta-Cel Transforms Treatment for Multiple Myeloma

ASH 2025 Expert Insights: Early Cilta-Cel Transforms Treatment for Multiple Myeloma

2025 American Society of Hematology Expert Insights: Early

Highlights in multiple myeloma from ASH 2024: anito-cel, bispecifics, and novel agents

Highlights in multiple myeloma from ASH 2024: anito-cel, bispecifics, and novel agents

In this interview, Rafael Fonseca,

ASH 2025 | CARTITUDE-4: Long-term PFS outcomes with cilta-cel for standard-risk RRMM

ASH 2025 | CARTITUDE-4: Long-term PFS outcomes with cilta-cel for standard-risk RRMM

During the 67th American Society of Hematology (